Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
288. Yetimalar Y, Gurgor N, Basoglu M (2004) Clinical efficacy <strong>of</strong> gabapentin for paroxysmal symptoms<br />
in multiple sclerosis. Acta Neurol Scand 109:430-431<br />
289. Yorkston KM, Spencer KA, Duffy JR, Beukelman DR, Golper LA, Miller RM, Strand RA, Sullivan M<br />
(2001) Evidence-based practice guidelines for dysarthria: management <strong>of</strong> velopharyngeal function.<br />
J Med Speech Lang Pathol 9:257-273<br />
290. Yorkston KM, Spencer KA, Duffy JR, Beukelman DR, Golper LA, Miller RM, Strand EA (2003) Behavioural<br />
management <strong>of</strong> respiratory/phonatory dysfunction from dysarthria: a systemic review <strong>of</strong><br />
the evidence. J Med Speech Lang Pathol 11:xiii-xxxviii<br />
291. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for<br />
treatment <strong>of</strong> spasticity and other symptoms related to multiple sclerosis (CA<strong>MS</strong> study): multicentre<br />
randomised placebo-controlled trial. Lancet 362:1517-1526<br />
292. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ,<br />
Thompson AJ (2005) Cannabinoids in multiple sclerosis (CA<strong>MS</strong>) study: safety and efficacy data for<br />
12 months follow up. J Neurol Neurosurg Psychiat 76: 1664-1669<br />
293. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL (1997) Lamotrigine (lamictal) in<br />
refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial.<br />
Pain 73:223-230<br />
294. Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, et al. (2003) <strong>Multiple</strong> sclerosis and<br />
depression: influence <strong>of</strong> interferon beta therapy. Mult Scler 9: 284-288<br />
295. Zifko UA, Rupp M, Schwarz S, Zifko HT, Maida EM (2002) Modafinil in treatment <strong>of</strong> fatigue in<br />
multiple sclerosis. Results <strong>of</strong> an open-label study. J Neurol 249: 983-987<br />
CORRESPONDING AUTHORS<br />
T Henze, MD t.henze@rz-ni.de<br />
Reha-Zentrum Nittenau, Rehabilitationsklinik für Neurologie – Geriatrie - Onkologie<br />
Eichendorffstr. 21, D-93149 Nittenau, Germany<br />
Phone +49 9436 950 800, Fax +49 9436 950 818<br />
KV Toyka, MD kv.toyka@uni-wuerzburg.de<br />
Dept. <strong>of</strong> Neurology, University <strong>of</strong> Würzburg<br />
Josef-Schneider-Str. 11, D-97080 Würzburg, Germany<br />
Phone +49 931 20123 756, Fax +49 931 20123 488<br />
P Rieckmann, MD, FRCPC prieckmann@brain.ubc.ca<br />
Division <strong>of</strong> Neurology, Dept <strong>of</strong> Medicine, University <strong>of</strong> British Columbia and Vancouver Coastal Health<br />
2211 Wesbrook Mall, Room S113-116, Vancouver BC Canada V6T 2B5<br />
61 E<strong>MS</strong>P, <strong>Symptomatic</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Multiple</strong> <strong>Sclerosis</strong>, December 2006 - revised in April 2008
Change language